Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
